Literature DB >> 15671429

Sodium channel mutations and susceptibility to heart failure and atrial fibrillation.

Timothy M Olson1, Virginia V Michels, Jeffrey D Ballew, Sandra P Reyna, Margaret L Karst, Kathleen J Herron, Steven C Horton, Richard J Rodeheffer, Jeffrey L Anderson.   

Abstract

CONTEXT: Dilated cardiomyopathy (DCM), a genetically heterogeneous disorder, causes heart failure and rhythm disturbances. The majority of identified DCM genes encode structural proteins of the contractile apparatus and cytoskeleton. Recently, genetic defects in calcium and potassium regulation have been discovered in patients with DCM, implicating an alternative disease mechanism. The full spectrum of genetic defects in DCM, however, has not been established.
OBJECTIVES: To identify a novel gene for DCM at a previously mapped locus, define the spectrum of mutations in this gene within a DCM cohort, and determine the frequency of DCM among relatives inheriting a mutation in this gene. DESIGN, SETTING, AND PARTICIPANTS: Refined mapping of a DCM locus on chromosome 3p in a multigenerational family and mutation scanning in 156 unrelated probands with DCM, prospectively identified at the Mayo Clinic between 1987 and 2004. Relatives underwent screening echocardiography and electrocardiography and DNA sample procurement. MAIN OUTCOME MEASURE: Correlation of identified mutations with cardiac phenotype.
RESULTS: Refined locus mapping revealed SCN5A, encoding the cardiac sodium channel, as a candidate gene. Mutation scans identified a missense mutation (D1275N) that cosegregated with an age-dependent, variably expressed phenotype of DCM, atrial fibrillation, impaired automaticity, and conduction delay. In the DCM cohort, additional missense (T220I, R814W, D1595H) and truncation (2550-2551insTG) SCN5A mutations, segregating with cardiac disease or arising de novo, were discovered in unrelated probands. Among individuals with an SCN5A mutation 27% had early features of DCM (mean age at diagnosis, 20.3 years), 38% had DCM (mean age at diagnosis, 47.9 years), and 43% had atrial fibrillation (mean age at diagnosis, 27.8 years).
CONCLUSIONS: Heritable SCN5A defects are associated with susceptibility to early-onset DCM and atrial fibrillation. Similar or even identical mutations may lead to heart failure, arrhythmia, or both.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671429      PMCID: PMC2039897          DOI: 10.1001/jama.293.4.447

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  38 in total

1.  Cardiac conduction defects associate with mutations in SCN5A.

Authors:  J J Schott; C Alshinawi; F Kyndt; V Probst; T M Hoorntje; M Hulsbeek; A A Wilde; D Escande; M M Mannens; H Le Marec
Journal:  Nat Genet       Date:  1999-09       Impact factor: 38.330

2.  Actin mutations in dilated cardiomyopathy, a heritable form of heart failure.

Authors:  T M Olson; V V Michels; S N Thibodeau; Y S Tai; M T Keating
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

Review 3.  Na+ channel activators as positive inotropic agents for the treatment of chronic heart failure.

Authors:  M Flesch; E Erdmann
Journal:  Cardiovasc Drugs Ther       Date:  2001-09       Impact factor: 3.727

4.  Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease.

Authors:  M K Baig; J H Goldman; A L Caforio; A S Coonar; P J Keeling; W J McKenna
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

5.  Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a.

Authors:  G Alex Papadatos; Polly M R Wallerstein; Catherine E G Head; Rosemary Ratcliff; Peter A Brady; Klaus Benndorf; Richard C Saumarez; Ann E O Trezise; Christopher L-H Huang; Jamie I Vandenberg; William H Colledge; Andrew A Grace
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

6.  Genetic basis and molecular mechanism for idiopathic ventricular fibrillation.

Authors:  Q Chen; G E Kirsch; D Zhang; R Brugada; J Brugada; P Brugada; D Potenza; A Moya; M Borggrefe; G Breithardt; R Ortiz-Lopez; Z Wang; C Antzelevitch; R E O'Brien; E Schulze-Bahr; M T Keating; J A Towbin; Q Wang
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

7.  Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias.

Authors:  Q Wang; M E Curran; I Splawski; T C Burn; J M Millholland; T J VanRaay; J Shen; K W Timothy; G M Vincent; T de Jager; P J Schwartz; J A Toubin; A J Moss; D L Atkinson; G M Landes; T D Connors; M T Keating
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

8.  Mutations in the muscle sodium channel gene (SCN4A) in 13 French families with hyperkalemic periodic paralysis and paramyotonia congenita: phenotype to genotype correlations and demonstration of the predominance of two mutations.

Authors:  E Plassart; J Reboul; C S Rime; D Recan; P Millasseau; B Eymard; J Pelletier; C Thomas; F Chapon; C Desnuelle
Journal:  Eur J Hum Genet       Date:  1994       Impact factor: 4.246

9.  Mapping a cardiomyopathy locus to chromosome 3p22-p25.

Authors:  T M Olson; M T Keating
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

10.  SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome.

Authors:  Q Wang; J Shen; I Splawski; D Atkinson; Z Li; J L Robinson; A J Moss; J A Towbin; M T Keating
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

View more
  168 in total

1.  Evaluation of Brugada syndrome by cardiac magnetic resonance.

Authors:  Carlo Tessa; Jacopo Del Meglio; Andrea Ghidini Ottonelli; Stefano Diciotti; Luca Salvatori; Massimo Magnacca; Marco Chioccioli; Jacopo Lera; Claudio Vignali; Giancarlo Casolo
Journal:  Int J Cardiovasc Imaging       Date:  2012-01-14       Impact factor: 2.357

Review 2.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

3.  Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy.

Authors:  Marwan M Refaat; Steven A Lubitz; Seiko Makino; Zahid Islam; J Michael Frangiskakis; Haider Mehdi; Rebecca Gutmann; Michael L Zhang; Heather L Bloom; Calum A MacRae; Samuel C Dudley; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Barry London; Patrick T Ellinor
Journal:  Heart Rhythm       Date:  2011-10-17       Impact factor: 6.343

Review 4.  Genetics of cardiac arrhythmias.

Authors:  Arthur A M Wilde; Connie R Bezzina
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

Review 5.  Inherited disorders of voltage-gated sodium channels.

Authors:  Alfred L George
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

6.  Novel SCN5A mutation in amiodarone-responsive multifocal ventricular ectopy-associated cardiomyopathy.

Authors:  Thomas M Beckermann; Karen McLeod; Victoria Murday; Franck Potet; Alfred L George
Journal:  Heart Rhythm       Date:  2014-05-09       Impact factor: 6.343

Review 7.  Mendelian forms of structural cardiovascular disease.

Authors:  Calum A MacRae
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

8.  Atrial Fibrillation and SCN5A Variants.

Authors:  Eleonora Savio-Galimberti; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

9.  The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy.

Authors:  Daniel Vega Møller; Paal Skytt Andersen; Paula Hedley; Mads Kristian Ersbøll; Henning Bundgaard; Johanna Moolman-Smook; Michael Christiansen; Lars Køber
Journal:  Eur J Hum Genet       Date:  2009-03-18       Impact factor: 4.246

10.  Prevalence of early-onset atrial fibrillation in congenital long QT syndrome.

Authors:  Jonathan N Johnson; David J Tester; James Perry; Benjamin A Salisbury; Carol R Reed; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2008-02-08       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.